Trial Details

Not Recruiting
Basic Information
Clinical ID c5484
Identifier ACTRN12616001031459
Trial Title PROxIMO: Efficacy of proactive therapeutic drug monitoring and dose adjustment of infliximab based on point of care testing for inflammatory bowel disease
Trial URL Visit Original Page
Study Information
Study Results

NULL
Conditions Ulcerative Colitis;Crohn's Disease; Ulcerative Colitis Crohn's Disease;Oral and Gastrointestinal - Crohn's disease;Oral and Gastrointestinal - Inflammatory bowel disease
Interventions The intervention will be prospective adjustments of infliximab dosing based on infliximab blood levels tested using a new point of care (POC) test, Quantum Blue Infliximab Assay, manufactured by Buhlmann Laboratories and approved for use in the European U
Participant Information
Sponsor Alfred Health Pharmacy Department
City NULL
Country/Region Australia
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT, ELDER, OLDER_ADULT
Study Design
Study Type Interventional
Phase PHASE4
Time Information
Start Date NULL
Primary Completion Date NULL
Completion Date NULL